TP53 and myelodysplastic syndrome: Nevertheless, as a highly disordered TF, there tends to be a huge number of variable gene positions causing missense and nonsense mutations in and beyond the DNA-binding domain, leading to mistaken misfolding and conformation of TP53, which makes it challenging to anchor a universal target, represented by the failure of Eprenetapopt234 (APR-246, a small molecule reactivating mutant and inactivated p53 protein) to meet the primary endpoint in a phase 3 trial of TP53-mutant myelodysplastic syndrome.